about
Increased Expression of Several Collagen Genes is Associated with Drug Resistance in Ovarian Cancer Cell LinesAnalysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines.Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell lineMicroarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines.The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance.Drug transporter expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line.Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell linesvPARP Adjusts MVP Expression in Drug-resistant Cell Lines in Conjunction with MDR Proteins.New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines.Effect of brefeldin A and castanospermine on resistant cell lines as supplements in anticancer therapy.Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines.Microarray-based detection and expression analysis of extracellular matrix proteins in drug‑resistant ovarian cancer cell lines.Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines.Nuclear localization of P-glycoprotein is responsible for protection of the nucleus from doxorubicin in the resistant LoVo cell line.MDR gene expression analysis of six drug-resistant ovarian cancer cell lines.Detection of a short CCR5 messenger RNA isoform in human spermatozoa.Effect of 5-azacytidine and procainamide on CD3-zeta chain expression in Jurkat T cells.The significance of lumican expression in ovarian cancer drug-resistant cell lines.The effect of high molecular weight dextran sulfate on the production of interleukin-8 in monocyte cell culture.Analysis of defective protein ubiquitylation associated to adriamycin resistant cells.New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines.Prevalence of ZAP-70, LAT, SLP-76, and DNA methyltransferase 1 expression in CD4+ T cells of patients with systemic lupus erythematosus.Quantitative analysis of CCR5 chemokine receptor and cytochrome P450 aromatase transcripts in swim-up spermatozoa isolated from fertile and infertile men.Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines.The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell LinesMutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance DevelopmentPTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like PopulationsTrichostatin A down-regulates ZAP-70, LAT and SLP-76 content in Jurkat T cellsTrichostatin A down-regulate DNA methyltransferase 1 in Jurkat T cellsThe Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer CellsSemaphorin 3A (SEMA3A), protocadherin 9 (PCdh9), and S100 calcium binding protein A3 (S100A3) as potential biomarkers of carcinogenesis and chemoresistance of different neoplasms, including ovarian cancer - review of literatureThe Significance of MicroRNAs Expression in Regulation of Extracellular Matrix and Other Drug Resistant Genes in Drug Resistant Ovarian Cancer Cell LinesExpression of Osteoblast-Specific Factor 2 (OSF-2, Periostin) Is Associated with Drug Resistance in Ovarian Cancer Cell Lines
P50
Q37068010-7A8889A7-215F-4662-9DBB-0484EAE28C74Q37349707-9ACAD829-CB39-4995-9EAE-B00351E69064Q37717845-9F801229-136A-469F-AB8E-38B47F6E8F1AQ38086655-275DBCBF-FE78-4754-96CE-96106A5DBD74Q38110652-3B521C0B-0371-463D-B9ED-830AA4274FA3Q38307214-CFC02EC7-1034-4604-B1E0-1CED6CDBC587Q38700421-F77F7641-9063-4F60-8930-1FCD74360485Q38702043-627A6E7B-2A77-4D44-AC16-1F39442BF78BQ38709065-ACE5986E-0434-47E6-9FE9-773F9F7948ACQ38785640-6E699477-182B-4309-AB56-2BEABE65C271Q38836932-2F1A8CA0-F069-42F4-B5FD-AC997BF63AF8Q38958642-762E5AA0-DB06-4991-B4DE-5CDBCD670CB0Q39076789-A6C7D5D6-D721-4581-8550-95589DD87F11Q39163572-A7AF84BD-E83E-4289-AEBB-1E2ECF30E335Q41483584-F7414CBE-C8E1-40C2-ACB3-87C3270A7732Q45005804-56326C7A-BE9A-4DB1-ABE9-BB9D5A45D9D0Q46408073-CF8BCEB6-FAD6-438E-97C5-1E8F2EB3B6FBQ47132524-568DCEA5-E488-43DC-BD0E-5A40A4281EF3Q47178721-69025653-ED0E-4401-886F-2C66A3C74151Q47445829-FF6F2D44-605C-4F2D-88BD-E6746B1E06CDQ48190854-050B2666-36B7-4765-8034-23DE751F43C7Q50684216-93691817-72EA-4C19-B6FC-8237BB7E01C1Q50721274-82FEDE14-D54A-4663-9758-D140F1C62288Q51626391-FE6E3093-B6B8-47E9-B71C-68075310D333Q59138332-7E21E96A-48A2-4142-BC3D-81C2BCB82E22Q60935573-99D36A75-55F3-4F06-B5FA-A3FEBBB24A14Q64253257-CD90E76F-57FF-44EC-B2C4-94B0EA5ABD24Q79441084-ED27C76E-A707-4B5C-9F7E-B2A69B951AB2Q83176706-BFC808E7-9958-4704-A081-23A1E7443C17Q91514807-EA12ADDC-AAB7-4689-951B-75C48B46E9ACQ91785777-D542DC7F-168A-4A36-990F-80AE7764D7E0Q91869298-A0F1610E-5AD5-4CBC-8D55-A153A7548963Q92619180-BFEC18CB-53CD-4A74-AD63-0A0360526C25
P50
description
researcher
@en
wetenschapper
@nl
name
R Januchowski
@en
R Januchowski
@nl
type
label
R Januchowski
@en
R Januchowski
@nl
prefLabel
R Januchowski
@en
R Januchowski
@nl
P106
P31
P496
0000-0001-7286-0657